UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Automated radiosynthesis of pharmaceutical grade [68Ga]Ga-NODAGA-Lys40-Exendin-4 and demonstration of its efficacy for use in patients

Journal of radioanalytical and nuclear chemistry, 2024-08, Vol.333 (8), p.3873-3891

2024

Volltextzugriff (PDF)

A method to prevail false positive responses due to excess cations and viscous nature of Radiopharmaceuticals in Limulus Amebocyte Lysate Gel Clot test

Asia oceania journal of nuclear medicine and biology, 2022-01, Vol.10 (2), p.109-116

2022

Volltextzugriff (PDF)

Intricacies in the Preparation of Patient Doses of [177Lu]Lu-Rituximab and [177Lu]Lu-Trastuzumab Using Low Specific Activity [177Lu]LuCl3: Methodological Aspects

Molecular imaging and biology, 2024-02, Vol.26 (1), p.61-80

2024

Volltextzugriff (PDF)

Radiochemical synthesis and pre-clinical evaluation of [68Ga]Ga-FAPI-4 formulated using in-house developed FAPI-4 kit

Journal of radioanalytical and nuclear chemistry, 2024-05

2024

Volltextzugriff (PDF)

Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma

Clinical nuclear medicine, 2024-04, Vol.49 (4), p.e149-e155

2024

Volltextzugriff (PDF)

Internal dosimetry and biodistribution of indigenously prepared 177Lu-DOTA-rituximab in lymphoma and other hematological malignancies treated with rituximab

Nuclear medicine communications, 2024-06

2024

Volltextzugriff (PDF)

Comparative evaluation of 177Lu-DOTATATE and 90Y-DOTATATE in SSTR II overexpressing Xenograft models for treatment of variable volume neuroendocrine tumours

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S213-S214

2022

Volltextzugriff (PDF)

P-302 - Comparative evaluation of 177Lu-DOTATATE and 90Y-DOTATATE in SSTR II overexpressing Xenograft models for treatment of variable volume neuroendocrine tumours

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S213-S214

2022

Volltextzugriff (PDF)

A robust lyophilized kit for convenient one-step formulation of [68Ga]Ga-DOTA-E−[c(RGDfK)]2 in hospital radiopharmacy for clinical PET imaging

Applied radiation and isotopes, 2023-06, Vol.196, p.110725-110725, Article 110725

2023

Volltextzugriff (PDF)

P-298 - Fully automated radiochemical synthesis of [68Ga]FAPI-4 and its preclinical evaluation for clinical translation

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S211-S212

2022

Volltextzugriff (PDF)

P-297 - Automated multidoses production of [68Ga]PentixaFor in general purpose commercial module and its preclinical evaluation in lymphoma model

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S211-S211

2022

Volltextzugriff (PDF)

In vitro study of 177Lu-DOTA-Trastuzumab and 177Lu-DOTA-Pertuzumab for evaluation of binding affinity towards human cell lines with differential expression of HER-2 receptor

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S213

2022

Volltextzugriff (PDF)

Radiochemical formulation of 177Lu-DOTA-trastuzumab: using low specific activity 177LuCl3

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S146

2022

Volltextzugriff (PDF)

P-301 - In vitro study of 177Lu-DOTA-Trastuzumab and 177Lu-DOTA-Pertuzumab for evaluation of binding affinity towards human cell lines with differential expression of HER-2 receptor

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S213-S213

2022

Volltextzugriff (PDF)

Fully automated radiochemical synthesis of [68Ga]FAPI-4 and its preclinical evaluation for clinical translation

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S211-S212

2022

Volltextzugriff (PDF)

Automated multidoses production of [68Ga]PentixaFor in general purpose commercial module and its preclinical evaluation in lymphoma model

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S211

2022

Volltextzugriff (PDF)

P-176 - Radiochemical formulation of 177Lu-DOTA-trastuzumab: using low specific activity 177LuCl3

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S146-S146

2022

Volltextzugriff (PDF)

Examining Absorbed Doses of Indigenously Developed 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy

Cancer biotherapy & radiopharmaceuticals, 2021-04, Vol.36 (3), p.292-304

2021

Volltextzugriff (PDF)

Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma

Clinical nuclear medicine, 2024-04, Vol.49 (4), p.e149

2024

Volltextzugriff (PDF)

Clinical Dose Preparation of [ 177 Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [ 177 Lu]LuCl 3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Cancer biotherapy & radiopharmaceuticals, 2022-06, Vol.37 (5), p.384-402

2022

Volltextzugriff (PDF)

Automated radiochemical synthesis of pharmaceutical grade [18F]FLT using 3‐N‐Boc‐5′‐O‐dimethoxytrityl‐3′‐O‐nosyl‐thymidine precursor and its Sep‐Pak® purification employing selective elution from reversed phase

Journal of labelled compounds & radiopharmaceuticals, 2022-06, Vol.65 (8), p.206-222

2022

Volltextzugriff (PDF)

Intricacies in the Preparation of Patient Doses of [ 177 Lu]Lu-Rituximab and [ 177 Lu]Lu-Trastuzumab Using Low Specific Activity [ 177 Lu]LuCl 3 : Methodological Aspects

Molecular imaging and biology, 2024-02, Vol.26 (1), p.61

2024

Volltextzugriff (PDF)

Melanoma Espial Employing Deep Learning Applied to Mobilenet

International journal for research in applied science and engineering technology, 2023-08, Vol.11 (8), p.2105-2111

2023

Volltextzugriff (PDF)

Pulmonary Hypertension - A Distinct Perspective

Journal of evidence based medicine and healthcare, 2021-06, Vol.8 (26), p.2349-2362

2021

Volltextzugriff (PDF)

Utilizing upper hybrid resonance for high density plasma production and negative ion generation in a downstream region

Journal of applied physics, 2012-09, Vol.112 (6)

2012

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Englisch
(79)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(21)
Humans
(14)
Original
(12)
Cardiac & Cardiovascular Systems
(10)
Cardiovascular System & Cardiology
(10)
Female
(10)
Physical Sciences
(9)
Male
(7)
Technology
(7)
Middle Aged
(6)
Plasma
(6)
Retrospective Studies
(6)
70 Plasma Physics And Fusion Technology
(5)
Animals
(5)
Coronary Heart Disease
(5)
Medical Research
(5)
Medicine, Experimental
(5)
Physics
(5)
Adult
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Automated radiosynthesis of pharmaceutical grade [68Ga]Ga-NODAGA-Lys40-Exendin-4 and demonstration of its efficacy for use in patients

A method to prevail false positive responses due to excess cations and viscous nature of Radiopharmaceuticals in Limulus Amebocyte Lysate Gel Clot test

Intricacies in the Preparation of Patient Doses of [177Lu]Lu-Rituximab and [177Lu]Lu-Trastuzumab Using Low Specific Activity [177Lu]LuCl3: Methodological Aspects

Radiochemical synthesis and pre-clinical evaluation of [68Ga]Ga-FAPI-4 formulated using in-house developed FAPI-4 kit

Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma

Internal dosimetry and biodistribution of indigenously prepared 177Lu-DOTA-rituximab in lymphoma and other hematological malignancies treated with rituximab

Comparative evaluation of 177Lu-DOTATATE and 90Y-DOTATATE in SSTR II overexpressing Xenograft models for treatment of variable volume neuroendocrine tumours

P-302 - Comparative evaluation of 177Lu-DOTATATE and 90Y-DOTATATE in SSTR II overexpressing Xenograft models for treatment of variable volume neuroendocrine tumours

A robust lyophilized kit for convenient one-step formulation of [68Ga]Ga-DOTA-E−[c(RGDfK)]2 in hospital radiopharmacy for clinical PET imaging

P-298 - Fully automated radiochemical synthesis of [68Ga]FAPI-4 and its preclinical evaluation for clinical translation

P-297 - Automated multidoses production of [68Ga]PentixaFor in general purpose commercial module and its preclinical evaluation in lymphoma model

In vitro study of 177Lu-DOTA-Trastuzumab and 177Lu-DOTA-Pertuzumab for evaluation of binding affinity towards human cell lines with differential expression of HER-2 receptor

Radiochemical formulation of 177Lu-DOTA-trastuzumab: using low specific activity 177LuCl3

P-301 - In vitro study of 177Lu-DOTA-Trastuzumab and 177Lu-DOTA-Pertuzumab for evaluation of binding affinity towards human cell lines with differential expression of HER-2 receptor

Fully automated radiochemical synthesis of [68Ga]FAPI-4 and its preclinical evaluation for clinical translation

Automated multidoses production of [68Ga]PentixaFor in general purpose commercial module and its preclinical evaluation in lymphoma model

P-176 - Radiochemical formulation of 177Lu-DOTA-trastuzumab: using low specific activity 177LuCl3

Examining Absorbed Doses of Indigenously Developed 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy

Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma

Clinical Dose Preparation of [ 177 Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [ 177 Lu]LuCl 3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Automated radiochemical synthesis of pharmaceutical grade [18F]FLT using 3‐N‐Boc‐5′‐O‐dimethoxytrityl‐3′‐O‐nosyl‐thymidine precursor and its Sep‐Pak® purification employing selective elution from reversed phase

Intricacies in the Preparation of Patient Doses of [ 177 Lu]Lu-Rituximab and [ 177 Lu]Lu-Trastuzumab Using Low Specific Activity [ 177 Lu]LuCl 3 : Methodological Aspects

Melanoma Espial Employing Deep Learning Applied to Mobilenet

Pulmonary Hypertension - A Distinct Perspective

Utilizing upper hybrid resonance for high density plasma production and negative ion generation in a downstream region

Suchergebnisse filtern